本文關(guān)鍵詞： 子癇前期 血栓素合酶 血栓素A2 血栓素受體 非吞噬細(xì)胞氧化酶1　出處：《福建醫(yī)科大學(xué)》2014年碩士論文　論文類型：學(xué)位論文

【摘要】：目的： 1.研究子癇前期組和正常妊娠組在年齡、終止孕周、孕婦血壓、新生兒出生體重、胎兒生長受限等方面的差異； 2.研究子癇前期患者胎盤中血栓素合酶（TXS）、血栓素A2（TXA2）、血栓素受體（TPr）及非吞噬細(xì)胞氧化酶1（NOX1）的表達(dá)情況，探討其與子癇前期發(fā)病的關(guān)系； 3.研究子癇前期患者胎盤TXA2表達(dá)與新生兒體重的關(guān)系； 4.研究子癇前期患者胎盤TPr通路與NOX1表達(dá)的關(guān)系。 方法： 1.收集子癇前期患者36例和正常孕婦34例，分析相關(guān)臨床資料 2.應(yīng)用免疫組化MaxVisionTM一步法檢測各組胎盤組織TXS、TPr、NOX1表達(dá)的位置、分布和表達(dá)量。 3.應(yīng)用實(shí)時(shí)熒光定量PCR（Real-Time PCR）定量檢測各組胎盤組織TXS、TPr、NOX1的mRNA表達(dá)量。 4. TXB2為TXA2的穩(wěn)定降解產(chǎn)物，應(yīng)用酶聯(lián)免疫吸附法（ELISA）定量檢測各組胎盤組織中TXB2的表達(dá)量，反映TXA2的表達(dá)情況。 結(jié)果： 1.兩組孕婦臨床資料分析結(jié)果顯示：兩組研究對象在年齡上差異無統(tǒng)計(jì)學(xué)意義（P0.05），但在終止孕周、收縮壓、舒張壓、平均動(dòng)脈壓和新生兒體重及胎兒生長受限方面差異有統(tǒng)計(jì)學(xué)意義（P0.01）。 2.免疫組化結(jié)果顯示： 2.1TXS蛋白主要表達(dá)于胎盤組織細(xì)胞滋養(yǎng)細(xì)胞、合體滋養(yǎng)細(xì)胞、少量絨毛血管內(nèi)皮細(xì)胞的胞漿中，，子癇前期組棕色染色明顯強(qiáng)于正常妊娠組染色，且差異有統(tǒng)計(jì)學(xué)意義（P0.01）。 2.2TPr蛋白主要表達(dá)于胎盤組織細(xì)胞滋養(yǎng)細(xì)胞、合體滋養(yǎng)細(xì)胞和絨毛血管內(nèi)皮細(xì)胞的胞漿中，子癇前期組棕色染色與正常妊娠組差異無統(tǒng)計(jì)學(xué)意義（P0.05）。 2.3NOX1蛋白主要表達(dá)于胎盤組織細(xì)胞滋養(yǎng)細(xì)胞、合體滋養(yǎng)細(xì)胞、絨毛血管內(nèi)皮細(xì)胞和間質(zhì)細(xì)胞的胞漿中。子癇前期組棕色染色明顯強(qiáng)于正常妊娠組染色，且差異有統(tǒng)計(jì)學(xué)意義（P0.01）。 3. Real-Time PCR結(jié)果顯示： 3.1子癇前期組胎盤TXS mRNA表達(dá)明顯強(qiáng)于正常妊娠組，且差異有統(tǒng)計(jì)學(xué)意義（P0.05）。 3.2子癇前期組胎盤TPr mRNA表達(dá)稍強(qiáng)于正常妊娠組，但差異無統(tǒng)計(jì)學(xué)意義（P0.05）。 3.3子癇前期組胎盤NOX1mRNA表達(dá)明顯強(qiáng)于正常妊娠組，且差異有統(tǒng)計(jì)學(xué)意義（P0.01）。 4. ELISA結(jié)果顯示： 4.1子癇前期組胎盤TXB2的表達(dá)量明顯高于正常妊組胎盤，且差異有統(tǒng)計(jì)學(xué)意義（P0.05）。 4.2子癇前期組胎盤TXB2表達(dá)量與新生兒體重呈負(fù)相關(guān)（r=-0.446，P0.01）。 4.3子癇前期組胎盤TXB2表達(dá)量和NOX1mRNA表達(dá)呈低度正相關(guān)（r=0.367，P0.05）。 結(jié)論：子癇前期胎盤組織TXS表達(dá)升高導(dǎo)致其催化的產(chǎn)物TXA2增加，TXA2通過激活其受體TPr而導(dǎo)致胎盤缺血缺氧，介導(dǎo)胎盤氧化應(yīng)激，同時(shí)TXA2可能通過激活TPr通路而促進(jìn)NOX1表達(dá)增加，導(dǎo)致胎盤產(chǎn)生過量ROS并向母體血液循環(huán)釋放，參與子癇前期的發(fā)病過程。
[Abstract]:Objective:. 1. To study the differences between preeclampsia group and normal pregnancy group in terms of age, termination of gestational week, maternal blood pressure, birth weight of newborn, fetal growth restriction and so on. 2. To study the expression of thromboxane synthase (TXS), thromboxane A2TXA2 (TPr2) and non-phagocytic oxidase 1 (NOX1) in placenta of patients with preeclampsia, and to explore its relationship with preeclampsia. 3. To study the relationship between placental TXA2 expression and neonatal weight in preeclampsia. 4. To study the relationship between placental TPr pathway and NOX1 expression in preeclampsia. Methods:. 1. 36 preeclampsia patients and 34 normal pregnant women were collected and the clinical data were analyzed. 2. The location, distribution and expression of TXS-1 in placenta were detected by immunohistochemical MaxVisionTM one-step method. 3. The expression of mRNA in placenta tissue of each group was detected by real-time fluorescence quantitative PCR(Real-Time. 4. TXB2 was the stable degradation product of TXA2. The expression of TXB2 in placenta of each group was quantitatively detected by enzyme linked immunosorbent assay (Elisa) to reflect the expression of TXA2. Results:. 1. The results of clinical data analysis of two groups of pregnant women showed that there was no significant difference in age between the two groups, but at the termination of gestational week, systolic blood pressure, diastolic blood pressure, There were significant differences in mean arterial pressure, neonatal body weight and fetal growth restriction (P 0.01). 2. The immunohistochemical results showed that:. 2.1TXS protein was mainly expressed in cytotrophoblast, syncytiotrophoblast and a small amount of villi vascular endothelial cells in placenta. The brown staining in preeclampsia group was significantly stronger than that in normal pregnancy group, and the difference was statistically significant (P 0.01). 2.2TPr protein was mainly expressed in cytotrophoblast, syntrophoblast and villi endothelial cell cytoplasm of placenta. There was no significant difference in brown staining between preeclampsia group and normal pregnancy group (P 0.05). 2.3NOX1 protein was mainly expressed in cytoplasm of trophoblast, syncytiotrophoblast, villi vascular endothelial cell and interstitial cell in placenta. Brown staining in preeclampsia group was stronger than that in normal pregnancy group, and the difference was statistically significant (P 0.01). 3.The Real-Time PCR result shows:. 3.1 the expression of TXS mRNA in placenta of preeclampsia group was significantly higher than that of normal pregnancy group, and the difference was statistically significant (P 0.05). 3.2 the expression of TPr mRNA in placenta of preeclampsia group was slightly higher than that of normal pregnancy group, but the difference was not statistically significant (P 0.05). 3.3 placental NOX1mRNA expression in preeclampsia group was significantly higher than that in normal pregnancy group (P 0.01). 4. The ELISA results show that:. 4.1 placental TXB2 expression in preeclampsia group was significantly higher than that in normal pregnancy group (P 0.05). 4.2 the expression of TXB2 in placenta of preeclampsia group was negatively correlated with neonatal body weight. 4.3 the expression of TXB2 and NOX1mRNA in the placenta of preeclampsia group was positively correlated with the expression of NOX1mRNA in the placenta of preeclampsia. Conclusion: the increase of TXS expression in placenta of preeclampsia leads to the increase of its catalytic product TXA2. TXA2 induces placental ischemia and hypoxia by activating its receptor TPr and mediates placental oxidative stress. Meanwhile, TXA2 may promote the expression of NOX1 by activating TPr pathway. The placenta produces excess ROS and releases to the maternal blood, which is involved in preeclampsia.
【學(xué)位授予單位】：福建醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R714.244


本文編號：1494210